Trial Profile
A Randomized, Controlled Interventional Phase 2b (Proof of Concept) Study of the Efficacy, Safety, and Tolerability of Repeated Intravitreal Administration of Ranibizumab Guided by Morphological Changes Documented by Optical Coherence Tomography (OCT) in Subjects With Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Dec 2018
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Branch retinal vein occlusion; Retinal oedema
- Focus Therapeutic Use
- Acronyms RabOCT
- 30 Nov 2018 Status changed from recruiting to completed.
- 30 Oct 2013 New trial record